Aclarion, Inc. has announced an At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC to offer and sell up to $1,075,000 of its common stock. The sales may be made from time to time through or to Ascendiant Capital Markets, acting as an agent or principal. Aclarion's common stock is quoted on the Nasdaq Capital Market under the symbol 'ACON', with the last reported sale price on September 23, 2024, being $0.1761 per share. The company also has IPO Warrants quoted under the symbol 'ACONW'. As of the date of the prospectus supplement, Aclarion's public float was valued at $3,247,370 based on a closing sale price of $0.3239 on July 26, 2024. The company has received deficiency letters from Nasdaq regarding compliance with the...Show More

Aclarion, Inc. has announced an At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC to offer and sell up to $1,075,000 of its common stock. The sales may be made from time to time through or to Ascendiant Capital Markets, acting as an agent or principal. Aclarion's common stock is quoted on the Nasdaq Capital Market under the symbol 'ACON', with the last reported sale price on September 23, 2024, being $0.1761 per share. The company also has IPO Warrants quoted under the symbol 'ACONW'. As of the date of the prospectus supplement, Aclarion's public float was valued at $3,247,370 based on a closing sale price of $0.3239 on July 26, 2024. The company has received deficiency letters from Nasdaq regarding compliance with the minimum bid price and stockholders' equity requirements. A reverse stock split has been approved by stockholders to assist in meeting Nasdaq's Bid Price Requirement. Aclarion has an appeal hearing scheduled on October 10, 2024, to address the delisting notice from Nasdaq. The company intends to use the net proceeds from this offering for market development, clinical evidence, product development, quality, general administration support, and other corporate purposes.